In this issue of JAMA Ophthalmology, the article by Mulligan and colleagues1 provides evidence to support the conclusion that vascular endothelial growth factor (VEGF) inhibitor therapy for neovascular age-related macular degeneration (AMD) may yield a substantial financial return on investment to patients and society, depending on the number of quality-adjusted life-years (QALYs) gained from treatment. With an increased frequency of injections (more frequent injections) of 10.5 fixed injections per year for 5 years vs approximately 8 injections per year (less frequent injections) for 5 years with a treat-and-extend regimen, the 5-year patient financial benefits compared with no treatment increased from $9.9 billion to $17.0 billion.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Brown MM, Brown GC. Economic Evaluation of Anti–Vascular Endothelial Growth Factor Therapy for Wet Age-Related Macular Degeneration. JAMA Ophthalmol. 2020;138(1):48–49. doi:10.1001/jamaophthalmol.2019.4582
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: